Innovation in European healthcare – what can Sweden learn? - LIF

The Health and Social Care Bill will expand the remit of NICE,
reduce variation and strengthen the compliance to NICE
technology appraisals throughout the NHS
NICE Implementation
Collaborative (NIC)
• The Government will establish the
NICE Implementation Collaborative
(NIC) to develop strategic
guidance and support
implementation of NICE approved
drugs.
• NIC will consist of NICE, the NHS
Commissioning Board, the Chief
Pharmaceutical Officer, main
industry bodies, the NHS
Confederation, the Clinical
Commissioning Coalition, and the
Royal Colleges.
• Some of its main initiatives are to:
– identify areas requiring support,
developing implementation guidance
and solutions for the NHS.
– help pharmaceutical companies to
improve their value propositions to
NICE.
– set out how use of existing tariff
flexibilities at a local level could further
support diffusion
NICE Compliance Regime
• The Government will introduce a NICE
Compliance Regime for the funding
direction attached to NICE technology
appraisals.
• The NICE Compliance Regime will
ensure rapid and consistent
implementation of clinical- and costeffective
technologies and medicines
throughout the NHS.
• Its will address local barriers to
accessing NICE technology appraisal
recommendations, with the exception
of clinical decisions relating to an
individual patient.
• The NICE Compliance Regime will
monitor the compliance of local
formularies failing to implement NICE
guidance.
Prioritizing and Re-designing
Local Formularies
• Standard processes in the design of
formularies have been lacking and
raising concerns that NICE technology
recommendations do not uniformly get
incorporated into all local formularies;
• The Government proposes that –
where clinically appropriate – NICE
Technology Appraisal
recommendations will automatically be
incorporated in to the local formularies
within 90 days of the completion of a
technology appraisal process.
• All PCT clusters in England will now
have to publish, no later than 1 April
2013, information on what NICE
recommended medicines and
technologies they have available for
patients.
– This will make data on local
formularies available as part of the
standard terms and conditions of NHS
contracts
– This is advantageous for
pharmaceutical companies who can
monitor the implementation and uptake
of their drugs at a local level
186